Pharma

Taking stock of the drug industry, from the lab to the medicine chest. For a weekly update, sign up for our free Pharmalot newsletter. And subscribe to STAT+ for exclusive coverage and analysis of the pharma industry — from drug pipelines to boardroom shakeups.

Pharma By Madlen Davies, Ivan Ruiz, Jill Langois, and Rosa Furneaux — The Bureau of Investigative Journalism

‘Held to ransom’: Pfizer plays hardball in Covid-19 vaccine negotiations with Latin American countries

Pfizer insisted some governments cover the potential costs of civil cases that result from its own acts of negligence, fraud, or malice.

Read The Story

Pharmalot By Ed Silverman

All Coverage

Pharmalot By Ed Silverman

Pharmalittle: Pfizer accused of ‘bullying’ some countries during vaccine talks; FDA to quickly analyze Covid-19 booster shots

Pharmalot By Ed Silverman

Pharmalittle: Glaxo and Sanofi start new trial of Covid-19 vaccine; AstraZeneca ends a drug’s use for bladder cancer after failed trial

Pharmalot By Ed Silverman

Up and down the ladder: The latest comings and goings

Pharmalot By Ed Silverman

Pharmalittle: Single Pfizer shot is 85% effective in preventing symptomatic Covid-19; Biden to commit $4 billion to COVAX

Pharmalot By Ed Silverman

Pharmalittle: Pfizer vaccine seems less potent against Covid-19 variant in lab test; WTO urges end to vaccine export restrictions

Pharmalot By Ed Silverman

‘Held to ransom’: Pfizer plays hardball in Covid-19 vaccine negotiations with Latin American countries

AbbVie smooths over a dispute about alleged theft of trade secrets for a new version of Botox

How nanotechnology helps mRNA Covid-19 vaccines work

New pledges boost COVAX, but critics say more is needed to ensure global vaccine access

Dozens of institutional investors push for ‘fair and equitable’ Covid-19 response

All Coverage

Pharmalittle: Pfizer accused of ‘bullying’ some countries during vaccine talks; FDA to quickly analyze Covid-19 booster shots

Pharmalittle: Glaxo and Sanofi start new trial of Covid-19 vaccine; AstraZeneca ends a drug’s use for bladder cancer after failed trial

Up and down the ladder: The latest comings and goings

Pharmalittle: Single Pfizer shot is 85% effective in preventing symptomatic Covid-19; Biden to commit $4 billion to COVAX

Pharmalittle: Pfizer vaccine seems less potent against Covid-19 variant in lab test; WTO urges end to vaccine export restrictions

Pharma’s ambitious new antibiotic venture hires a CEO to fix a ‘broken’ pipeline

Pharmalittle: First Covid-19 human challenge study to begin; vaccine firm executives profit from insider stock sales

Ultra-rare but not forgotten: New drug development paradigms to treat the rarest of diseases

Novartis and the Gates Foundation aim to create a more practical gene therapy for sickle cell patients around the world

FDA warns AcelRx of misleading ads for its pain drug Dsuvia

After a controversial Alzheimer’s drug review, FDA’s Woodcock rejects proposal to ‘firewall’ agency review staff

Pharmalittle: WHO approves AstraZeneca Covid-19 vaccine; North Korean hackers target Pfizer vaccine data

Bristol Myers and Sanofi ordered to pay $834 million to Hawaii for withholding Plavix label

Once again, senators want GAO to probe the role of PBMs in prescription drug pricing

Up and down the ladder: The latest comings and goings

Pharmalittle: An arthritis drug reduced Covid-19 death rates; impatience grows over choosing FDA commissioner

By looking the other way, pharma money helped fuel a toxic political atmosphere in the U.S.

With a legislative vote, Maryland’s prescription drug affordability board moves forward

Arthritis drug cuts deaths in hospitalized Covid-19 patients, major study shows

Pharmalittle: Teva and Merck may help with Covid-19 vaccine production; $5 billion Gilead deal goes up in flames

Drug maker agrees to plead guilty to hiding and destroying records before FDA inspection

Drug maker will slash prices on cancer medicines to end price gouging probe in Europe

Pharmalittle: House Dems slip drug pricing proposal into Covid-19 relief bill; FDA grants emergency use for Lilly drug

To the delight of generic drug makers, federal appeals court tosses controversial ‘skinny labeling’ decision